ABSTRACT
In August 1989, the U.S. Food and Drug Administration (FDA) made it clear to members of the generic drug industry that many aspects of current good manufacturing practices (cGMPs) apply to the product development process. The unfortunate problems uncovered at that time led agency investigators to request, for the first time, records showing how formulations were developed. Disappointingly, many firms had little documentation related to product development activities.
